Had to do this...too good to not have grabbed the below
Had to do this...too good to not have grabbed the below post from the 'other' place (ty jimmy667). Ritz - I'm with you, Nader is relentless and a bit off beat, most people who defy odds have to be that way. I know if I put 10+ years in my life dedicated to a single thing, I sure as heck won't give up easy..I trust the bulldog to win the fight. See everyone in a few months.
=======================================
The results of CD12 added $5 billion (at a minimum) to the value of CytoDyn. It has just not shown up in the market cap....yet.
Let this sink in....all the BP drugs and trials have failed. Only
Dexamethasone has shown reliable utility for Covid....it comes with a high price...organ failure.
CytoDyn drug did not fail...it showed remarkable signal...the trial was flawed in several ways as it was designed in the early days of the pandemic. It needed a larger N of critical and a different design.
Most all the other BP trials ended in terminal failure. Most drugs need to have several Phase 3s on the way to approval.
Most of other drugs are not getting that chance.
CytoDyn has a fairly quick and sure path to approval. I can not stress enough the immense value of the knowledge gained in these two prior trials in designing this likely last trial for acute Covid. Then there is the long haulers trial...again Leronlimab is ahead here as well as one of the only drugs in the race.
If this were a scam there would not be a cacophony of shrill voices calling it such.
This is a disruptive drug for a possible multitude of indications. The company has a eccentric CEO .....Steve Jobs was fired at Apple. Everyone thought Elon Musk was an dreamer in the early years and that his vision would never succeed.
Say what you will about Nader but the man has vision.
How many metals did Edison test before he found tungsten?
The short sighted see CD12 as a failure. It is but one step along the way.
Nearly all Biotechs face stumbling blocks. Where so many warn of danger is the time and place of opportunity...on the path to success.
23
1
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Unpacking Bascom's Jasmine Acquisition In a market that's been more slippery than a greased pig, Bascom Group's move buying up Jasmine Apartments is capturing some eyes. Situated in North Dallas, this 370-unit complex ain't just another brick in the wall—it's Bascom's 42nd entry into Texas, reinforcing their knack for sniffing out deals others might tiptoe around,...
Continue Reading
Debt Reality: A National Concern with Global Implications When it comes to the U.S. federal debt situation, the latest report from the National Seniors Policy Center is lighting a fire like no other, warning us that we're not crying wolf here. We've got fiscal numbers that may not sit well at breakfast. With roughly 67 cents of every new buck Uncle Sam borrows going to...
Continue Reading
Young Artists Called to Inspire a Cancer-Free World What's the first image that pops into your head when you think of a world free from cancer? That's the magic question on deck for this year's Youth Art Contest by Debbie's Dream Foundation. Imaginations are set to run wild as the competition opens its gates to artists under 18, calling for visions splashed across...
Continue Reading
Navigating the AI Terrain in Arbitration It's 2026 and artificial intelligence isn't just a buzzword anymore; it's reshaping every corner of how disputes get resolved. The American Arbitration Association (AAA) has jumped into the mix, launching an AI Ambassador program to tackle a wave of AI-induced challenges. These aren't just academic exercises—this is a hard-nosed...
Continue Reading
A Month to Celebrate Unseen Heroes Take a pause. We're talking about National Service Dog Month. What in the world could be more endearing than a pack of puppies, those hopeful bundles of joy, destined to grow up and play pivotal roles in people's lives? Canine Companions is rolling out the red carpet for these future heroes, with a nine-day Puppy Cam event from September...
Continue Reading
Revolutionizing Viticulture with Data In today's wild world, climate change isn't just shifting weather patterns—it's upending the age-old map of wine-making regions. We've got a new player on the field: the World Winery Map. It's digital, massive, and it’s shaking things up for winemakers and grape enthusiasts alike. This platform covers a staggering 4.3 million...
Continue Reading
Big Moves in the Financial Advisory World Let's dive right in. Here's a real shakeup in the advisory realm: 28 financial advisors and team members from Sierra Ridge Advisor Group are packing their bags for Gateway Financial Partners. We're talking about a significant shift involving $825 million in assets under advisement. Instead of sticking with Sierra Ridge as it...
Continue Reading
The AI Mentor Battleground in Education Ever found yourself wondering how public schools could step up their game without dumping money down the tech rabbit hole? ETERC’s latest push with Ele may just be a game-changer for them. We're not talking about your run-of-the-mill chatbot regurgitating facts from the internet—this is an AI tricked out for personalized...
Continue Reading
The Folding Bike Revolution: More Than Just a Fad You've seen them zipping around—those compact, folding bikes. They're not just for urban commuters looking to save space. Oh no, this is a full-blown cycling revolution we're talking about. DAHON, a name that's been rolling since 1982, has been riding these waves and making strides that others can only dream of. While...
Continue Reading
New Kid on the Block: Cheez Nugs Buckle up folks, Crimson Coward is at it again. They're rolling out something they claim will blow your taste buds straight out of the water: Cheez Nugs. Dropping nationwide on September 18, 2026, these aren't your run-of-the-mill cheese bites. We're talking 100% whole-milk mozzarella, a golden herb-seasoned crust, and a mouthful of creamy...
Continue Reading
Top 5 Most Recently Viewed Articles
Subtle Asset Management's Strategic Acquisition Subtle Asset Management has made headlines with its recent acquisition of a remarkable commercial property for $9.68 million. This new asset, comprising 73,882 square feet, is strategically located and includes a blend of office and retail spaces designed to serve the community. Major tenants include the Social Security...
Continue Reading
What's Going Down at Richtech Robotics? Alright, folks, gather ‘round, because this is one of those wake-up calls that reminds you why we keep our heads on a swivel in this wild market. Richtech Robotics Inc. (NASDAQ: RR) is under fire as investors find themselves at the heart of a potential securities fraud lawsuit, and boy, does it stink. That Schall Law Firm is...
Continue Reading
Introducing Athernal Bio and Its Mission Athernal Bio is making its debut in the biotech industry with an exciting announcement about securing £3.5 million in funding from Delin Ventures. The company is on a groundbreaking path to develop targeted immunotherapies aimed at combating high-risk clonal haematopoiesis (CH), a precursor to various types of blood cancers,...
Continue Reading
Cousins Properties Schedules Earnings Release and Call Cousins Properties (CUZ) has officially announced the timing for its fourth quarter earnings release for the year 2024. This important event is set to take place after market hours on a specified Thursday evening. Earnings Conference Call Details The live conference call to discuss the earnings results is planned for...
Continue Reading
Understanding the Recent Investigations of KinderCare Learning Companies, Inc. Pomerantz LLP has initiated investigations concerning investor claims related to KinderCare Learning Companies, Inc. (NYSE: KLC). As one of the leading firms specializing in corporate and securities litigation, Pomerantz is dedicated to ensuring that investors are informed of any developments...
Continue Reading